 | • レポートコード：B-MOR-08318 • 出版社/出版日：Mordor Intelligence / 2018年5月1日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、肺がん手術の世界市場について調べ、肺がん手術の世界規模、市場動向、市場環境、タイプ別（区域切除 、肺葉切除、肺切除、スリーブ切除）分析、製品別（手術器具、モニタリング装置）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・肺がん手術の世界市場インサイト ・肺がん手術の世界市場環境 ・肺がん手術の世界市場動向 ・肺がん手術の世界市場規模 ・肺がん手術の世界市場規模：タイプ別（区域切除 、肺葉切除、肺切除、スリーブ切除） ・肺がん手術の世界市場規模：製品別（手術器具、モニタリング装置） ・肺がん手術の世界市場：地域別市場規模・分析 ・肺がん手術の北米市場規模・予測 ・肺がん手術のアメリカ市場規模・予測 ・肺がん手術のヨーロッパ市場規模・予測 ・肺がん手術のアジア市場規模・予測 ・肺がん手術の日本市場規模・予測 ・肺がん手術の中国市場規模・予測 ・肺がん手術のインド市場規模・予測 ・肺がん手術の韓国市場規模・予測 ・関連企業情報・競争状況 |
The Lung cancer surgery Market is expected to register a CAGR of about 7%, during the forecast period, 2018 to 2023. Lung Cancer is the lethal lung tumor portrayed by the undisciplined growth of cells in the lung tissues. The interpretation of lung cancer is confirmed by biopsy which is carried out using bronchoscopy or CT-guidance. Lung cancer surgery is the surgical ablation of cancer tissue from the lung. The type of surgery depends upon the size of the tumor and its position within the lung.
Rise in the Level of Air Pollution
According to a recent report, lung cancer constitutes 6.9% of all new cancer cases and 9.3% of all cancer-related deaths in both men and women. The two main types of carcinomas are small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC). About 10% to 15% of non-smokers are also at risk. The WHO’s International Agency for Research on Cancer has classified outdoor air pollution as a carcinogen. Rising levels of pollution are leading to increased incidences of lung cancer. This acts as a driver for the market of lung cancer surgery. Along with this, majority of lung cancer cases are a result of long-term tobacco smoking. With the rising number of smokers, more people are getting affected by lung cancer. Also, the technological advancements in the field of lung cancer surgery and rise in incidences of lung cancer will together act as drivers for the lung cancer surgery market.
Effective Alternative Treatment
Surgery has been the most prescribed form of treatment for patients with stage I non-small cell lung cancer. However, with the association of morbidity and mortality with surgery in the geriatric population remain a matter of concern. Along with this, the 5-year survival rates are also poor. However, with the availability of newer nonsurgical treatment options such as stereotactic radiation therapy (SRT) and radiofrequency ablation (RFA) the patients are considering opting for these treatment options. This acts as a restraining factor the lung cancer surgery market.
North America to Substantial Growth in the Market
North America will dominate the lung cancer surgery market due to the technological advancements in the field of lung cancer surgery. Europe will also show substantial growth in lung cancer surgery market as there is an increasing incidences of lung diseases. APAC consists of most of the countries with poor pollution regulations and major cities in countries, like China, India and Indonesia to be highly polluted, causing lung cancer in a huge population. Therefore, there will be a considerable growth in the lung cancer surgery market.
Key Developments in the Market
• November 2017 – Sysmex Acquired CLIA Waiver for New Automated Lung cancer surgery Analyzer—The First Automated Lung cancer surgery Analyzer to Receive Such Approval
Major players- ACCURAY, ETHICON, GE HEALTHCARE, JOHNSON & JOHNSON, OLYMPUS, RICHARD WOLF AND SIEMENS HEALTHCARE, amongst others.
Reasons to Purchase this Report
• Current and future for lung cancer surgery market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rise in Incidences of Lung Cancer
6.1.2 Technological Advancements in the Field of Minimally Invasive Surgeries
6.1.3 Rise in the Level of Air Pollution
6.2 Market Restraints
6.2.1 Effective Alternative Treatment
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Types
7.1.1 Segmentectomy
7.1.2 Lobectomy
7.1.3 Pneumonectomy
7.1.4 Sleeve Resection
7.2 By Products
7.2.1 Surgical Devices
7.2.2 Monitoring Devices
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Accuray
9.2 Ethicon
9.3 GE Healthcare
9.4 Johnson & Johnson
9.5 Olympus
9.6 Richard Wolf
9.7 Siemens Healthcare
9.8 List Not exhaustive
10. Future of the Market